286 related articles for article (PubMed ID: 31485460)
1. Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?
Ferrari SM; Fallahi P; Ruffilli I; Elia G; Ragusa F; Paparo SR; Patrizio A; Mazzi V; Colaci M; Giuggioli D; Ferri C; Antonelli A
J Immunol Res; 2019; 2019():5878960. PubMed ID: 31485460
[TBL] [Abstract][Full Text] [Related]
2. Regulatory polymorphism of CXCL10 rs1439490 in seronegative occult hepatitis C virus infection.
Wang X; Wang S; Liu ZH; Qi WQ; Zhang Q; Zhang YG; Sun DR; Xu Y; Wang HG; Li ZX; Cong XL; Zhao P; Zhou CY; Wang JB
World J Gastroenterol; 2018 May; 24(20):2191-2202. PubMed ID: 29853737
[TBL] [Abstract][Full Text] [Related]
3. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
5. Chemokines in the Pathogenesis and as Therapeutical Markers and Targets of HCV Chronic Infection and HCV Extrahepatic Manifestations.
Fallahi P; Ferrari SM; Giuggioli D; Sebastiani M; Colaci M; Ferri C; Antonelli A
Curr Drug Targets; 2017; 18(7):786-793. PubMed ID: 26240054
[TBL] [Abstract][Full Text] [Related]
6. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
Fattovich G; Covolo L; Bibert S; Askarieh G; Lagging M; Clément S; Malerba G; Pasino M; Guido M; Puoti M; Gaeta GB; Santantonio T; Raimondo G; Bruno R; Bochud PY; Donato F; Negro F;
Aliment Pharmacol Ther; 2011 May; 33(10):1162-72. PubMed ID: 21443535
[TBL] [Abstract][Full Text] [Related]
7. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
Antonelli A; Ferrari SM; Giuggioli D; Ferrannini E; Ferri C; Fallahi P
Autoimmun Rev; 2014 Mar; 13(3):272-80. PubMed ID: 24189283
[TBL] [Abstract][Full Text] [Related]
8. Soluble inflammatory markers as predictors of virological response in patients with chronic hepatitis C virus infection treated with interferon-α plus ribavirin.
Moura AS; Carmo RA; Teixeira AL; Teixeira MM; Rocha MO
Mem Inst Oswaldo Cruz; 2011 Feb; 106(1):38-43. PubMed ID: 21340353
[TBL] [Abstract][Full Text] [Related]
9. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
Ogurtsov PP; Kukhareva EI
Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
[TBL] [Abstract][Full Text] [Related]
10. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
[TBL] [Abstract][Full Text] [Related]
11. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
[TBL] [Abstract][Full Text] [Related]
12. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
[TBL] [Abstract][Full Text] [Related]
13. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
Meissner EG; Decalf J; Casrouge A; Masur H; Kottilil S; Albert ML; Duffy D
PLoS One; 2015; 10(7):e0133236. PubMed ID: 26181438
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.
Arnaud C; Pradat P; Spaziante M; Berthillon P; Maynard M; Taliani G; Chemin I; Trépo C; Petit MA
Antivir Ther; 2013; 18(8):1027-32. PubMed ID: 23948510
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
16. CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients.
Pineda-Tenor D; Berenguer J; Jiménez-Sousa MA; Guzmán-Fulgencio M; Aldámiz-Echevarria T; Carrero A; García-Álvarez M; Diez C; Tejerina F; Briz V; Resino S
J Clin Virol; 2014 Nov; 61(3):423-9. PubMed ID: 25218243
[TBL] [Abstract][Full Text] [Related]
17. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
18. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
Reiberger T; Aberle JH; Kundi M; Kohrgruber N; Rieger A; Gangl A; Holzmann H; Peck-Radosavljevic M
Antivir Ther; 2008; 13(8):969-76. PubMed ID: 19195322
[TBL] [Abstract][Full Text] [Related]
19. Interleukin- 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response.
Resham S; Manzoor S; Imran M; Saalim M; Naseem S; Azam S
APMIS; 2015 Sep; 123(9):765-71. PubMed ID: 26177560
[TBL] [Abstract][Full Text] [Related]
20. Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin.
Zeremski M; Dimova RB; Benjamin S; Penney MS; Botfield MC; Talal AH
J Infect Dis; 2015 Jun; 211(11):1795-9. PubMed ID: 25512630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
